lung [16] and breast [17] cancers. In studies evaluating therapies in non-curative settings, progression-free survival (PFS), and time to progression (TTP) provide information about biological activity and may indicate benefit for some patients [18, 19] however they are not reliable surrogates for improved survival [18, [20] [21] [22] [23] or QoL [23, 24] .
To date there is no standard tool for grading the magnitude of clinical benefit of cancer therapies [25, 26] , which may range from trivial (median PFS advantage of only a few weeks) to substantial (improved long term survival). Indeed, in the absence of a standardised approach for grading the magnitude of clinical benefit, conclusions and recommendations derived from studies are often hotly disputed [25] and very modest incremental advances have often been presented, discussed and promoted as major advances or " breakthroughs" [5, [25] [26] [27] [28] [29] . Overestimating or overstating the benefits from new intervention can cause harm: It confounds public policy decision making [29] , undermines the credibility of oncology research reporting [26, 29, 30] , harms patients who choose to undertake treatments based on exaggerated expectations that may subject them to either risk of adverse effects, inconvenience or substantial personal costs [26, 28] and in the public domain they fuel sometimes inappropriate hype or disproportionate expectations about novel treatments [31, 32] and the need to allocate public or personal funds to provide them.
It is important for the Oncology Community to present clear and unbiased statements regarding the magnitude of clinical benefit from new therapeutic approaches supported by credible research. ESMO aims to highlight those treatments which bring substantial improvements to the duration of survival and/or the QoL of cancer patients which need to be distinguished from those whose benefits are more modest, limited or even marginal. To this end, ESMO has undertaken the development of a validated and reproducible tool to assess the magnitude of clinical benefit of anti-cancer interventions, the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS). ESMO intends to apply this scale prospectively to each new anti-cancer drug/intervention that will be European Medicines Agency (EMA) approved. Drugs or treatment interventions that obtain the highest scores on the scale will be highlighted in the ESMO guidelines, with the hope that they will be rapidly endorsed by health authorities across the European Union. The second generation draft (ESMO-MCBS v-1.0) was formulated based on the feedback from faculty and biostatisticians and the conceptual work of Alberto Sobrero regarding the integration of both hazard ratio (HR), prognosis and absolute differences in data interpretation [33, 34] . The second generation draft was applied in a wide range of contemporary and historical disease settings by members of the ESMO-MCBS Task Force, the ESMO Guidelines Committee and a range of invited experts. Results were scrutinised for face validity, coherence and consistency. Where deficiencies were observed or reported, targeted modifications were implemented and the process of field testing and review was repeated. This process was repeated through 13 redrafts of the scale preceding the current one (ESMO-MCBS v1.0). The final version and fielded testing results were reviewed by selected members of the ESMO faculty and the ESMO Executive Board.
The goal of the ESMO-MCBS evaluation was to assign the highest grade to trials having adequate power for a relevant magnitude of benefit, and to make appropriate grade adjustment to reflect the observed magnitude of benefit. To achieve this goal, a dual rule was implemented; first, taking into account the variability of the estimated HR from a study, the lower limit of the 95% Confidence Interval (CI) for the HR is compared to specified threshold values; and second the observed absolute difference in treatment outcomes is compared to the minimum absolute gain considered as beneficial. Different candidate threshold values for HR and absolute gains for survival, DFS and PFS, adjusted to represent as accurately as possible the expert opinion of the oncology community, have been explored through extensive simulations. The finally implemented combined thresholds for the HR and the minimum observed benefit that could be considered as deserving the highest grade in both the curative and non-curative setting are outlined in Table 2 .
In all forms HR thresholds refer to the lower extreme of the 95% CI (Figure 2 ). The performance of the evaluation rule based on the lower limit of the 95% CI of HR, was compared to the simpler rule of using a cut-off for the point estimate of HR, in conjunction with the additional rule on the minimum absolute gain in treatment outcome. The simulation results under different HR values and corresponding power, favoured the proposed approach to use the lower limit of the 95% CI which takes into account the variability of the estimate. The correspondence between an HR value and the minimum absolute gain considered as beneficial according to the ESMO-MCBS, is presented by median survival (OS or PFS) for standard treatment, in Figure 2 . For example, for a standard treatment median survival of 6 months, an absolute gain of 3 months corresponds to an HR=0.67, while a gain of 1.5 months corresponds to an HR=0.8.
the ESMO magnitude of clinical benefit scale (ESMO-MCBS v1.0) (Appendix I)
The ESMO Magnitude of Clinical Benefit Scale version 1 (ESMO-MCBS v1.0) has been developed only for solid cancers. Given the profound differences between the curative and palliative settings the tool is presented in two parts. Form 1 is used to evaluate adjuvant and other treatments with curative intent. Form 2 (a, b or c) is used to evaluate non-curative interventions, with form 2a for studies with OS as the primary outcome, form 2b for studies with PFS or TTP as primary outcomes, 2c for studies with QoL, toxicity or response rate as primary outcomes and for non-inferiority studies. Form 2a is prognostically sub-stratified for studies where the control arm produced OS greater or less than or equal to 1 year and form 2b for studies where the control arm produced PFS greater or less than or equal to 6 months.
eligibility for application of the ESMO-MCBS
The ESMO-MCBS can be applied to comparative outcome studies evaluating the relative benefit of treatments using outcomes of survival, QoL, surrogate outcomes for survival or QoL (DFI, EFS, TTR, PFS and TTP) or treatment toxicity in solid cancers. Eligible studies can have either a randomised or comparative cohort design [35, 36] or a meta-analysis which report statistically significant benefit from any one, or more of the evaluated outcomes.When more than one study has evaluated a single clinical question, results derived from well powered registration trials should be given priority.
Studies with pre-planned subgroup analyses with a maximum of 3 subgroups can be scored.
When statistically significant results are reported for more than one subgroup, then each of these should be evaluated separately. Subgroups not showing statistically significant results are not graded. Except for studies that incorporate collection of tissue samples to enable restratification based on new genetic or other biomarkers, findings from un-planned (posthoc) subgroup analysis cannot be graded and they can only be used as foundation for hypothesis generation. 2b: This version is used for therapies evaluated using a primary endpoint of PFS or TTP. The form is stratified by median duration of PFS of the control arm <6 months and >6 months.
The maximal preliminary score is discounted to 3 because PFS and TTP are surrogate outcomes with a less reliable relationship to improved survival or QoL [18, [20] [21] [22] [23] . In studies that allow crossover on subsequent therapy, this may be the best available evidence of activity since subsequent therapies may reduce the likelihood of observing survival benefit. Preliminary scores derived from PFS studies can be upgraded or downgraded depending on secondary outcomes such as toxicity data, improvement in OS or data derived from QoL evaluation. This form incorporates an adverse effect criterion for downgrading in cases of severe toxicity compared to the control arm. If an OS advantage is observed as a secondary outcome, scores are upgraded using the scale on form 2a. In PFS studies that evaluate global QoL, positive findings (as evidenced by statistically significant improvement in global QoL or delayed deterioration in QoL) will upgrade the evaluation by 1 point and, in the absence of survival advantage, the absence of QoL advantage will result in a downgrading by 1 point.
2c: This form is used for therapies evaluated in non-inferiority (equivalence) studies and for studies in which the primary outcomes are QoL, toxicity or response rate (RR).
field testing of ESMO-MCBS
ESMO-MCBS has been applied in a wide range of solid tumours by members of the ESMO-MCBS Task Force, the ESMO Guidelines Committee and a range of invited experts (Tables 3-12 ). When discrepancies between graders were observed, this was generally related to either inaccurate data extraction, variable interpretation of the significance and severity of toxicity data, or errors in applying the data to the correct grading criteria.
Discussion inherent challenges in developing standard clinical benefit scale
The substantial variability of study designs (crossover, non-crossover, and partial crossover), planned outcomes and reported outcomes inherently challenge the process of developing a unified scale of clinical benefit. This challenge is all the greater in an era in which both researchers and regulatory authorities are employing surrogate outcome indicators as primary end points for both research and registration criteria [5] . A unified scaling approach requires a process of relative weighting of evidence that demands conceptual rigor, careful reviews of the validity and strength of surrogate endpoints and clinical nuance.
validity of the ESMO-MCBS
The ESMO-MCBS version 1 (ESMO-MCBS v1.0) provides an objective and reproducible approach that allows comparisons of the magnitude of benefit between studies that incorporate different primary outcomes (OS, PFS, QoL) and different designs through a process of variable weighting of primary outcomes and adjustments for significant secondary outcomes and toxicity.
The development process has been compliant with the criteria for "accountability for reasonableness" which represent the ethical gold-standard for a fair priority setting process in public policy [43, 44] . The validity of the ESMO-MCBS is derived from 1) Clinically relevant and reasonable criteria for prioritisation of different types of benefit, i.e. that cure takes precedence over deferral of death, direct endpoints such as survival and QoL take precedence over less reliable surrogates such as PFS or RR and that the interpretation of the evidence for benefit derived from indirect primary outcomes (such as PFS, or RR) may be influenced by secondary outcome data, 2) Coherence: Procedural agreements regarding the evidence to be used/not used, how it will be analysed and evaluated, and precautions to minimising bias (including conflict of interest issues) based upon an understanding of the relative strengths and weaknesses of the usual measured outcomes OS and QoL, and their surrogates [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] 45 
limitations of the ESMO-MCBS v1.0
The ESMO-MCBS can only be applied to comparative research outcomes; it is therefore not applicable when evidence of benefit derives from single arm studies. This limits its utility in the uncommon situation in which registration is granted on the basis of outcomes reported from single arm studies.
The process of relative weighting of evidence and the thresholds for HR and absolute gains involves judgments and subjective considerations which are amenable to dispute and challenge and indeed, this is invited as part of the dynamic process of peer-review and further development. Crossover:Crossover, or subsequent treatment of control arm patients with biologically similar agent, severely compromises the ability to derive reliable data regarding the survival advantage of treatments in phase III studies. This factor may impact on OS results as illustrated by the study of dacarbazine vs ipilimumab in metastatic melanoma [51] in which the evidence for survival advantage was diluted by the crossover provision in the study. In some instances in which strong PFS advantage is seen, crossover of this type will obscure the potential survival benefit of the new treatment. Statistical approaches to estimate longer-term clinical outcomes despite substantial treatment crossover have been developed [52, 53] , and applied [54] [55] [56] [57] . While these approaches are encouraging they incorporate a range of assumptions and are not universally accepted [58] .
Unbalanced crossover: In other instances, unbalanced crossover may exaggerate differences in survival. For instance in the PEAK study comparing FOLFOX6 with either bevacizumab or panitumumab among the patients with KRAS wild type tumours, only 38% of those in the bevacizumab arm received any EGFR antibody in subsequent therapy [59] .
Although this study showed a survival advantage of 9.9 months over a baseline of 24.3 months for patient initiated on treatment with panitumumab, it remains unclear as to whether this was affected by the sequence of treatments or if it was the result that more than half of the patients in the bevacizumab arm were never exposed to an EGFR antibody.
Follow up reports:
In some studies first reports are followed up with subsequent further relevant data analysis. This is particularly true when mature survival data was not available in studies with a primary outcome of PFS or DFS and in studies that have incorporated post hoc stratification based on refined appreciation of tumour biology that may impact on outcome evaluation.
Both of these phenomena were observed in the three publications reporting the findings from the same study on FOLFOX4 +/-panitumumab for the first-line treatment of KRAS wild type colorectal cancer [60] [61] [62] . The study, which did allow for crossover to other EGFR antibodies, had PFS as a primary endpoint. The initial publication demonstrated a modest PFS advantage with non-significant median OS gain [60] . The subsequent publicationof mature data demonstrated a significant OS gain [61] with the greatest benefit restricted to patients with KRAS, NRAS, BRAF wild typetumours [62] . Almost identical data maturation was observed in the CRYSTAL study evaluating FOLFIRI+/-cetuxumab in the same clinical setting [63] [64] [65] .
Maturation of survival data also increased the ESMO-MCBS score of vemurafenib in the treatment of metastatic melanoma [66, 67] from ESMO MCBS 3 based on PFS to 4, based on OS.
using data from the ESMO-MCBS
The ESMO-MCBS incorporates a structured, rational and valid approach to data interpretation and analysis that reduces the tendency to have judgments affected by bias or uninformed and/or idiosyncratic data interpretation. Consequently, application of the scale reduces the likelihood that statements of clinical benefit will be distorted by either overestimation or overstatement on one extreme or, nihilism at the other. This structured and disciplined approach to deriving estimates of clinically meaningful benefit from published data can be used in a range of settings.
Public policy applications:Grading derived from the ESMO-MCBS provides a backbone for value evaluations for cancer medicines. Medicines and therapies that fall into the ESMO-MCBS A+B for curative therapies and 4+5 for non-curative therapies should be highlighted for accelerated assessment of value and cost effectiveness. While a high ESMO-MCBS score does not automatically imply high value (that depends on the price), the scale can be utilised by to frame such considerations [68] and can help public policy-makers advance "accountability for reasonableness"in resource allocation deliberations [43, 44] . well conducted phase III studies relative to lower levels such as that derived from nonrandomised studies, anecdote or expert clinical opinion. A major shortcoming of this approach is that it may result in a high level of evidence irrespective of the actual magnitude of the benefit observed, even if the magnitude of the benefit is very limited [69] . This discrepancy has been highlighted by the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group which was formed in 2000 to improve the quality of guideline formulation. The GRADE working group emphasised that a particular quality of evidence does not necessarily imply a particular strength of recommendation [70, 71] . They have developed and championed a widely endorsed approach emphasising appropriate framing of research and guideline questions [72] , evaluation of the strength of recommendations that incorporates evaluation of the balance between desirable and undesirable outcomes (estimated effects), and the confidence in the magnitude effect of the interventions on important outcomes [73] .
Formulation of Clinical Guidelines
This recommendation can be accomplished by describing both the level of benefit and the level of evidence for recommended therapeutic interventions. For cancer therapies, the ESMO-MCBS scale provides a clear, well-structured and validated mechanism to indicate the magnitude of benefit in addition to the level of evidence that can inform both national and international (e.g. ESMO) guidelines. 
Conclusion
ESMO is committed to promoting rational, responsible and affordable cancer care, the importance of organisational integrity, and the promotion of best use of limited health care resources. The ESMO-MCBS v-1.0 was born out of these considerations. It represents a first version of a well validated tool to stratify the magnitude of clinical benefit for new anticancer treatments and is applicable over a full range of solid tumours. Based on the data derived from well-structured phase III clinical trials or meta-analyses, the tool uses a rational, structured and consistent approach to derive a relative ranking of the magnitude of benefit that can be anticipated from any new treatment. The ESMO-MCBS is an important first step to the major ongoing task of evaluating value in cancer care which is essential for appropriate uses of limited public and personal resources for affordable cancer care. The ESMO-MCBS will be a dynamic tool and its criteria will be revised on a regular basis pending peer reviewed feedback and developments in cancer research and therapies. 
